The recent report of an antisense oligonucleotide therapy designed for only one patient spotlights regulatory, economic and ethical issues that must be grappled with in an era of accelerated development of ‘ultra-personalized’ drugs.

中文翻译：

---

个人化的成本。

最近针对仅一名患者设计的反义寡核苷酸疗法的报告聚焦于在“超个性化”药物加速发展的时代必须解决的监管，经济和道德问题。